Navigation Links
Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
Date:5/24/2010

MORRISTOWN, N.J., May 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg strengths, the generic equivalent to GlaxoSmithKline, LLC's VALTREX® tablets. Watson intends to begin shipping the product shortly.  

VALTREX® 500 and 1000 mg had total U.S. sales of approximately $1.8 billion for the twelve months ending March 2010, according to IMS Health.  Valacyclovir hydrochloride tablets are indicated for treatment of cold sores (herpes labialis), initial episodes of genital herpes in immunocompetent adults, recurrent episodes of genital herpes in immunocompetent adults, chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults, the reduction of transmission of genital herpes in immunocompetent adults, and the treatment of herpes zoster (shingles) in immunocompetent adults.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

VALTREX® is a registered trademark of GlaxoSmithKline, LLC.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Version of LIPITOR® in Canada
2. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
3. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
4. Mylan Receives Approval for Generic Version of Zyban(R)
5. Par Obtains Exclusive Rights to Market and Distribute Generic Zetia(R) in the U.S.
6. Mylan Receives Approval for Generic Version of Flomax(R)
7. Actavis Launches Generic Version of Flomax(R) In The U.S.
8. FDA Consumer Health Information - Generic Drug Roundup: April 2010
9. Physicians Eagerly Await Xarelto but Generic Price Advantage Could be a Sticking Point
10. Watson Receives FDA Approval for Generic Cardizem(R) LA
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According to ... a majority of oncology patients undergo imaging screenings without understanding the nuanced risks associated ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... May 27, 2016 Hutchison ... company focused on the highly lucrative global oncology ... pipeline of potential first-in-class or best-in-class tyrosine kinase ... development with strategic partners. HCM,s profitable Chinese healthcare ... market. We expect progress of the mid-to-late-stage pipeline ...
(Date:5/27/2016)... NEW YORK , May 27, 2016 ... with biotechs, drug manufacturers, health insurance companies all falling ... very small healthcare companies. While not often talked about, ... The United States is by ... the world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... new Concussion Clinic serving South Florida. , The clinic is led by ... pediatric physical medicine and rehabilitation, pediatric neuropsychology and also a team of certified ...
(Date:5/31/2016)... Linda, CA (PRWEB) , ... ... ... an approach to healthcare that considers individuals’ genetic characteristics and the physical ... and precision therapy work in sync. In personalized medicine, diagnosing an individual’s ...
(Date:5/31/2016)... ... 31, 2016 , ... St. Joseph Medical Center (SJMC) announced ... which enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, ... the exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... back to particular advertising campaigns, to monitor the performance of sales and support ... maximize conversions and revenue. The software allows customers to record, transcribe, route, document, ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
Breaking Medicine News(10 mins):